The first medical device powered by artificial intelligence and designed to help doctors detect skin cancer was cleared for marketing by the U.S. Food and Drug Administration.
Although not meant to be used as a primary screening tool, the technology evaluates skin lesions that doctors have already flagged as suspicious, according to the FDA.
Physicians who are not dermatologists can use the device to evaluate skin lesions suggestive of melanoma, basal cell carcinoma or squamous cell carcinoma in patients 40 and older to determine whether to refer a patient to a dermatologist.
Full Story: FDA
The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.